• 1. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 2. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 3. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425

Introduction to 1-(6-Methylpyridin-3-yl)ethanamine dihydrochloride (CAS No. 2089381-50-8)

1-(6-Methylpyridin-3-yl)ethanamine dihydrochloride, identified by its Chemical Abstracts Service (CAS) number 2089381-50-8, is a significant compound in the realm of pharmaceutical and biochemical research. This compound belongs to the class of pyridine derivatives, which have garnered considerable attention due to their diverse biological activities and potential therapeutic applications. The structural framework of this molecule incorporates a pyridine ring substituted with a methyl group at the 6-position and an ethylamine moiety at the 3-position, further modified into its dihydrochloride salt form for enhanced solubility and stability.

The pyridine core of 1-(6-Methylpyridin-3-yl)ethanamine dihydrochloride is a privileged scaffold in medicinal chemistry, known for its ability to interact with various biological targets. Pyridine derivatives have been extensively studied for their roles in modulating enzyme activity, receptor binding, and signal transduction pathways. The presence of the methyl group at the 6-position influences the electronic properties of the ring, thereby affecting its interactions with biological molecules. This modification can enhance binding affinity or alter metabolic stability, making it a critical factor in drug design.

The ethylamine side chain at the 3-position introduces basicity to the molecule, which is often exploited to improve pharmacokinetic properties such as blood-brain barrier penetration or renal clearance. The conversion of this compound into its dihydrochloride salt form not only enhances its solubility in aqueous solutions but also ensures better crystallinity and shelf-life stability, making it a preferred form for both preclinical and clinical studies.

Recent advancements in computational chemistry and structure-based drug design have highlighted the importance of 1-(6-Methylpyridin-3-yl)ethanamine dihydrochloride as a lead compound for developing novel therapeutics. Its structural features make it a versatile building block for synthesizing analogs with tailored biological activities. For instance, studies have demonstrated its potential in inhibiting certain kinases and transcription factors, which are implicated in cancer progression and inflammatory diseases.

In the context of oncology research, 1-(6-Methylpyridin-3-yl)ethanamine dihydrochloride has been investigated for its ability to disrupt aberrant signaling pathways in tumor cells. Preliminary in vitro studies suggest that this compound can modulate the activity of specific enzymes involved in cell proliferation and survival. The methylpyridine moiety appears to be crucial for binding to target proteins, while the ethylamine group contributes to fine-tuning the interaction kinetics. These findings align with broader trends in oncology where small-molecule inhibitors targeting post-translational modifications are gaining prominence.

Beyond oncology, this compound has shown promise in preclinical models of neurodegenerative disorders. The pyridine scaffold is known to interact with neuronal receptors and ion channels, making it a candidate for developing treatments against conditions such as Alzheimer's disease and Parkinson's disease. The 6-methylpyridine derivative has been reported to cross the blood-brain barrier more efficiently compared to unsubstituted pyridines, which is a critical factor for central nervous system (CNS) drug development.

The synthesis of 1-(6-Methylpyridin-3-yl)ethanamine dihydrochloride involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Common synthetic routes include nucleophilic substitution reactions followed by salt formation. Advances in green chemistry have also led to the development of more sustainable methods for producing this compound, emphasizing minimal waste generation and energy efficiency.

Evaluation of 1-(6-Methylpyridin-3-yl)ethanamine dihydrochloride in animal models has provided valuable insights into its pharmacokinetic profile. Studies indicate that it exhibits moderate oral bioavailability and prolonged half-life, suggesting potential for once-daily dosing regimens. Additionally, preliminary toxicity studies have shown that it is well-tolerated at therapeutic doses, although further investigations are warranted to assess long-term safety.

The role of computational modeling in optimizing 1-(6-Methylpyridin-3-yl)ethanamine dihydrochloride cannot be overstated. Molecular docking simulations have been used to predict binding affinities with various biological targets, aiding in rational drug design. These simulations help identify key interactions between the molecule and its intended target proteins, allowing chemists to modify specific regions for improved efficacy.

Future directions in research may explore derivatization strategies to enhance the therapeutic potential of 1-(6-Methylpyridin-3-yl)ethanamine dihydrochloride. For example, introducing additional functional groups could modify its solubility or metabolic stability while retaining or enhancing biological activity. Collaborative efforts between synthetic chemists and biologists will be essential in translating these findings into clinical applications.

In conclusion,1-(6-Methylpyridin-3-yl)ethanamine dihydrochloride (CAS No. 2089381-50-8) represents a promising compound with significant potential in pharmaceutical research. Its unique structural features make it a valuable scaffold for developing novel therapeutics targeting various diseases, particularly cancer and neurodegenerative disorders. Continued investigation into its mechanisms of action and optimization strategies will likely yield innovative treatments that address unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)